Incremental Costs in Giant Cell Arteritis

Mounié, Michaël; Costa, Nadège; Sailler, L.; Lapeyre‐Mestre, Maryse; Bourrel, Robert; Savy, Nicolas; Molinier, Laurent; Pugnet, G.

doi:10.1002/acr.23429

Cited by 10 publications

(6 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Higher use of outpatient physician, laboratory, and radiology visits, and ophthalmologic procedures were responsible for the increased cost of care, accounting for a median incremental cost attributed to GCA over a 5-year period of $4662, if compared to a matched referent cohort in the USA, and amounting to €1342 for the first 6 months, €1498 between 6 and 12 months, and €1165 between 12 and 18 months in France. 33,34 In our cohort, the overall estimated direct healthcare cost was €2374 per patient-year, and it was largely determined by the costs for hospitalizations (70%) and medications (27.5%), clearly highlighting the most important outcome for new treatments (i.e. the lowering of the hospitalization rate for GCA).…”

Section: Medical Costsmentioning

confidence: 93%

Data linkage analysis of giant cell arteritis in Italy: Healthcare burden and cost of illness in the Italian region of Friuli Venezia Giulia (2001–2017)

et al. 2019

View full text Add to dashboard Cite

Giant cell arteritis (GCA) is the most common vasculitis in adults. However, comprehensive analyses of the healthcare burden are still scarce. The aim of the study is to report the healthcare burden and cost of illness of GCA in the Friuli Venezia Giulia (FVG) region of Italy, based on a data linkage analysis. To this end, a retrospective study was conducted through the integration of many administrative health databases of the FVG region as the source of information. Cases were identified from two verified, partially overlapping sources (the rare disease registry and medical exemption database). From 2001 to 2017, 208 patients with GCA were registered. The prevalence of GCA in the population aged ⩾ 45 years as of December 31, 2017 was 27.2/100,000 inhabitants (95% CI 23.5–31.4). The mean time of observation was 4.5 ± 3.6 years. A total of 3182 visits (338 per 100 patient-years) was recorded. The most frequent specialty visits were rheumatology ( n = 610, 19.2%), followed by internal medicine ( n = 564, 17.7%). A total of 287 hospitalizations (30 per 100 patient-years) were reported. A total of 13,043 prescriptions (1386 per 100 patient-years) were registered. More than half of the patients were prescribed an immunosuppressive agent. The overall estimated direct healthcare cost was €2,234,070, corresponding to €2374 per patient-year. Overall, GCA is a rare disease which implies a high healthcare cost.

show abstract

Section: Medical Costsmentioning

confidence: 93%

Data linkage analysis of giant cell arteritis in Italy: Healthcare burden and cost of illness in the Italian region of Friuli Venezia Giulia (2001–2017)

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Our study adds valuable information for the cost of illness (COI) for hospitalized vasculitis patients. Mounie et al [ 14 ] and Babingura et al [ 13 ] both studied the incremental costs of GCA compared to the controls, but they received very distinct results within the first year, €2840 vs. $16,431, respectively. Mounie et al [ 14 ] speculated that the difference is partly explained by the societal perspective and the differences in health care systems.…”

Section: Discussionmentioning

confidence: 99%

“…Mounie et al [ 14 ] and Babingura et al [ 13 ] both studied the incremental costs of GCA compared to the controls, but they received very distinct results within the first year, €2840 vs. $16,431, respectively. Mounie et al [ 14 ] speculated that the difference is partly explained by the societal perspective and the differences in health care systems. In our study, we recorded the COI of systemic vasculitis including GCA, and the median costs for GCA patients within 12 months was €6605.2.…”

Section: Discussionmentioning

confidence: 99%

“…Babigumira et al reported that the US patients with a new GCA diagnosis had substantially higher health care costs compared to the patients without GCA; the difference in 1-year cost was $16,431 (95% CI $13,821–$19,041) [ 13 ]. In 2017, a French study showed that the cumulative incremental cost during the first 3 years of GCA exceeded €6400 compared to matched controls, representing an adjusted increase of 72% of costs [ 14 ]. In GPA, a US study reported that hospitalization is on average $17,000 higher in cost per admission than in non-GPA patients [ 15 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The Delay and Costs of Diagnosing Systemic Vasculitis in a Tertiary-Level Clinic

2020

View full text Add to dashboard Cite

Introduction The diagnosis of systemic vasculitis is a challenge because of the heterogeneity of clinical manifestations. The aim of this study is to analyze the diagnostic delay in systemic vasculitis, the total costs during the first year of care, and how the diagnostic delay affects the costs in a tertiary health care facility. Methods Patients with a new diagnosis of systemic vasculitis between 2010 and 2018 were identified from hospital records. The diagnostic delay and health care costs were evaluated during the diagnostic period and within 12 months after the first contact with tertiary health care. Vasculitis-related costs were recorded as true costs charged. A total of 317 patients fulfilled the study criteria. The diagnoses were grouped into three clinically relevant groups: IgA vasculitis and other small-vessel vasculitis ( n = 64), ANCA-associated vasculitis (AAV) ( n = 112), and large-vessel vasculitis (LVV) ( n = 141). Results The diagnostic delay from the first referral to tertiary-level clinic was shortest in the LVV group and longest in the AAV group . Total costs during the diagnostic period were the highest in the AAV group (median = €6754 [IQR €8812]) and lowest in the LVV group (median = €3123 [IQR €4517]), p < 0.001. There was a significant positive correlation between the diagnostic delay and total costs during the diagnostic period and 12 months ( r s = 0.38, p < 0.001 and r s = 0.34, p < 0.001, respectively). In a linear model, the inpatient days and the number of laboratory tests were the strongest predictors ( p < 0.001) of a higher treatment cost during the diagnostic period. Conclusions There is a substantial diagnostic delay that correlates significantly with the costs in tertiary-level health care when diagnosing systemic vasculitis. Electronic supplementary material The online version of this article (10.1007/s40744-020-00266-9) contains supplementary material, which is available to authorized users.

show abstract

“…Data used in pharmacoepidemiology and particularly those coming from claims databases are by definition completely accurate for a pharmacoeconomics' point of view. A study performed on the SNDS at a regional level has described the economic burden of the giant cell arteritis (GCA) [40].…”

Section: Pharmacoeconomicsmentioning

confidence: 99%

The challenges of pharmacoepidemiology of orphan drugs in rare diseases

Lapeyre‐Mestre

2020

Therapies

Self Cite

View full text Add to dashboard Cite

Incremental Costs in Giant Cell Arteritis

Abstract: This study provides an accurate assessment of GCA costs during a 5-year period and gives useful information for future cost-effectiveness studies based on new expensive biotherapies.

Cited by 10 publications

References 46 publications

Data linkage analysis of giant cell arteritis in Italy: Healthcare burden and cost of illness in the Italian region of Friuli Venezia Giulia (2001–2017)

Data linkage analysis of giant cell arteritis in Italy: Healthcare burden and cost of illness in the Italian region of Friuli Venezia Giulia (2001–2017)

The Delay and Costs of Diagnosing Systemic Vasculitis in a Tertiary-Level Clinic

The challenges of pharmacoepidemiology of orphan drugs in rare diseases

Contact Info

Product

Resources

About